Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04011306
Other study ID # CEP-06-001
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date February 2020
Est. completion date August 2021

Study information

Verified date January 2020
Source Rogers Sciences Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary purpose of this feasibility study is to evaluate safety and effectiveness in healing outcomes of patients treated with Lumina24TM BLU (treatment), a Continuous Low-Irradiance Phototherapy (CLIP) device, as compared to standard of care (SOC) therapy (control) for the treatment of acute burns.


Description:

This feasibility study will consist of up to 15 subjects (Cohort I: up to 10 subjects with partial thickness second-degree burns; Cohort II: up to 5 subjects with deep partial thickness second- and/or full thickness third-degree burns). Each subject will be randomized to receive standard of care dressing on approximately half of the study burn site, and Lumina24TM BLU treatment on the remaining half of the study burn site. If the subject has bilaterally symmetric burns, they will be randomized to receive SOC or Lumina24TM BLU at the distinct anatomical burn locations (e.g. right/left thigh, right/left shoulder, etc.). The proposed feasibility study will inform critical primary and secondary outcome measures and procedural improvements necessary for a pivotal clinical study that would demonstrate both antimicrobial effectiveness and improved wound healing of acute burn wounds.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 15
Est. completion date August 2021
Est. primary completion date August 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Males or females age > 18 to < 65

- BMI > 20 kg/m2

- Patients anticipated to receive inpatient care for a minimum of 72 hours at the respective medical facility for partial thickness second-degree, deep partial thickness second-degree and/or full thickness third-degree burn wounds.

- Patients who have a > 5% to < 50% Total Body Surface Area (TBSA) wound.

- Patients are willing and able to adhere to the therapy and protocol.

- Female of childbearing potential must be willing to use acceptable methods of contraception.

- Patients may or may not have clinical signs and symptoms of burn site infection at baseline.

- Subject has read, understood and signed the approved ICF before screening procedures either by the patient or their legally authorized representative.

Exclusion Criteria:

- Subjects with burns > third-degree (i.e. involvement of deeper tissues, such as muscle, tendons, or bone)

- Patients deemed not medically stable by the treating Investigator.

- Patients with burn wounds limited to their head or genitalia.

- Patients currently enrolled or participating in another investigational device, drug or biological trial that would interfere with the Lumina24TM application.

- Patients with inhalation burns.

- Patients who are clinically septic.

- Patients are pregnant.

- Patients on a ventilator, who are undergoing acute fluid resuscitation, are hemodynamically unstable or are deemed 'comfort measures only'.

- In the opinion of treating physician, patient not expected to survive beyond 30 days.

- Pregnant or lactating status. Pregnancy as determined by a positive pregnancy test at screening or baseline.

- Known history of HIV infection, or active Hepatitis B or Hepatitis C infection.

- Cancer requiring chemotherapy or radiation within previous 6 months or resection within the last 5 years (other than basal cell carcinoma.

- Known chronic renal failure (serum creatine > 2 mg/dL) or chronic liver disease.

- Pre-existing medical condition requiring current use of immunosuppressive medication or systemic steroids

- Pre-existing medical conditions that would interfere with wound healing (i.e. diabetic patients with Hemoglobin A1c test result > 8%, malignancy, autoimmune disease)

- Subjects with psychiatric conditions that are anticipated to result in protocol noncompliance

- Chronic illicit drug or alcohol abuse that is anticipated to interfere with patient compliance with the protocol

- Subject is incarcerated at the time of screening.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Lumina24 BLU
Lumina24 BLU is the technology used to deliver continuous low-irradiance phototherapy for the treatment of acute burns

Locations

Country Name City State
United States University of Florida Gainesville Florida

Sponsors (1)

Lead Sponsor Collaborator
Rogers Sciences Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Wound Healing Percentage area reduction (PAR) of the acute burn wound (SOC control site vs. Lumina24TM BLU treatment site) up to 28 days
Primary Number of adverse events Safety measured by incidence of product-related AEs, SAEs, and UADEs up to 28 days
Primary Microbial load counts (Cohort II only) Difference of bioburden in/on the burn wound (SOC control site vs. Lumina24TM BLU treatment site) assessed by quantitative analysis of microbial load counts obtained from 3-mm punch biopsies and wound cultures up to 28 days
Secondary Time to healing Time to burn wound healing at end of inpatient treatment 12 months
Secondary Numerical Pain Rating Scale Difference in pain related to acute burn wounds between SOC control site and Lumina24TM BLU treatment site assessed by patient-reported rating ranging from 0 to 10 (where 0 represents no pain and 10 represents worst possible pain) 12 months
Secondary Cost-effectiveness Difference in cost-effectiveness of treatment regime between Lumina24TM BLU and SOC control assessed by difference in sum of costs associated with each treatment regime (including costs of OR visits required, inpatient stay, grafts and/or biologics used) 12 months
Secondary Patient and Observer Scar Assessment Scale Difference in healing of hypertrophic scarring between SOC control site and Lumina24TM BLU treatment site assessed by Patient and Observer Scar Assessment Scale 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT03948360 - Safety Study of a Novel Wearable Phototherapy System for the Management of Acute Burn Wounds N/A
Completed NCT04277182 - Effect of Propolis Application on Burn Healing N/A
Enrolling by invitation NCT00978705 - Clinical Efficacy and Safety of Autologous Cultured Keratinocyte Cell on Severe Burn Wood Phase 3
Withdrawn NCT03675568 - Non-cultured Autologous Keratinocyte Suspension Versus Traditional Split Skin Graft for Burn Wounds Treatment N/A
Active, not recruiting NCT04828304 - PLASOMA Ultimate Safety & Efficacy Study N/A
Not yet recruiting NCT05649332 - Study to Evaluate the Performance and Safety of the Medical Device Argogen N/A
Recruiting NCT05593523 - Fluorescence-based Detection of Inflammation and Necrosis to Inform Surgical Decision-making and Enhance Outcomes
Completed NCT06280053 - HealiAid in the Treatment of Different Wounds N/A
Enrolling by invitation NCT06103409 - MSCs for the Treatment of Burn Wounds Phase 1/Phase 2
Recruiting NCT05796492 - Ultrasound Treatment on Wound Healing Time N/A
Enrolling by invitation NCT04725071 - Immunonutrition Supplementation for Improved Burn Wound Healing in Older Adults N/A
Suspended NCT02577120 - Wound Healing Endpoint and Recurrence Phase 4
Active, not recruiting NCT05341427 - DEVELOPMENT OF A CLINICAL PREDICTION RULES TO IDENTIFY EFFICACY OF PULSED ELECTROMAGNETIC THERAPY ON BURN WOUND HEALING N/A
Completed NCT04753723 - The Use of a Platform Wound Device for Reducing Infection Phase 4
Terminated NCT03723590 - A Clinical Evaluation of an Esterified Hyaluronic Acid Matrix in Burn Patients for STSG N/A
Recruiting NCT05404191 - Prediction Rules for Low Level Laser on Burn Wounds N/A
Completed NCT02982096 - Study Comparing Healing With Epidermal Fractional Blistergrafting (CellutomeTM) to Acellular Technique N/A